Last reviewed · How we verify
Alcaftadine Ophthalmic Solution 0.25%
Antihistamine
Antihistamine Used for Allergic conjunctivitis.
At a glance
| Generic name | Alcaftadine Ophthalmic Solution 0.25% |
|---|---|
| Also known as | Lastacaft® |
| Sponsor | Allergan |
| Drug class | Antihistamine |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
Alcaftadine is an antihistamine that selectively inhibits the histamine H1 receptor.
Approved indications
- Allergic conjunctivitis
Common side effects
- Eye irritation
- Headache
- Dry mouth
Key clinical trials
- Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea
- Safety and Efficacy Study of a Eye Drop for Eye Allergy (PHASE3)
- A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis (PHASE4)
- A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alcaftadine Ophthalmic Solution 0.25% CI brief — competitive landscape report
- Alcaftadine Ophthalmic Solution 0.25% updates RSS · CI watch RSS
- Allergan portfolio CI